Weiqiang Zhao
Harbin Institute of Technology
ORCID: 0000-0001-6560-2780Also affiliated with The Ohio State University Wexner Medical Center
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 6 papers. Top paper: “Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study”.
Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum +9 more
Susan M. Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy +12 more
Dawei Zhou, Guillaume Fiches, Zhenyu Wu, Xuefeng Liu, Qin Ma +4 more
Adam D. Kenney, Jun‐Gyu Park, Guillaume Fiches, Helu Liu, Dawei Zhou +8 more
Thurbu Tshering Lepcha, Dawei Zhou, Zhixian He, Guillaume Fiches, Youngmin Park +10 more
Hui Liu, Weiqiang Zhao, Ying Su, Jinyun Yan